Hoechst Pakistan Limited (PSX:HPL)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
3,971.16
-29.72 (-0.74%)
At close: Mar 6, 2026
Market Cap38.30B +39.7%
Revenue (ttm)30.96B +15.7%
Net Income2.90B +56.2%
EPS301.67 +56.7%
Shares Out9.64M
PE Ratio13.16
Forward PEn/a
Dividend240.00 (6.04%)
Ex-Dividend DateApr 1, 2026
Volume193
Average Volume852
Open3,981.20
Previous Close4,000.88
Day's Range3,901.00 - 4,098.99
52-Week Range2,876.00 - 4,889.99
Beta0.33
RSI32.35
Earnings DateFeb 18, 2026

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its allergy management, anti-diarrheals, antiemetic, antibiotic, cardiology, consumer healthcare, diabetes, and emergency care products under Flagyl, Clexane, Lantus, Amaryl, Claforan, Haemaccel, Secnidazole forte, Rulid, Targocid, Tavanic, Tarivid, Aventriax, Stemetil, Lasix, Winstor, Tritace, Cordarone, CoAprovel, Aprovel, CoPlavix, Selsun Blue, Apidra, Toujeo, Soliqu... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 837
Stock Exchange Pakistan Stock Exchange
Ticker Symbol HPL
Full Company Profile

Financial Performance

In 2025, Hoechst Pakistan's revenue was 30.96 billion, an increase of 15.73% compared to the previous year's 26.75 billion. Earnings were 2.90 billion, an increase of 56.16%.

Financial Statements